Biotech has been one of 2026’s standout trades, and one of its most misunderstood. The sector’s benchmark exchange-traded fund, the SPDR S&P Biotech ETF (XBI), is up roughly 23–24% year to date, more than double the S&P 500’s gain, while the iShares Biotechnology ETF (IBB) has risen about 24%. The rally has been powered by genuine scientific progress, a surge in pharmaceutical dealmaking and a financing market that reopened after the long “biotech winter” of 2024 and early 2025.
But the headline claim that biotech stocks are simply “surging” is now only half the story. The XBI peaked at 169.55 in mid-August, fell below 150 by late September and was trading near 149.5 as of Oct. 23, according to Investing.com data — roughly 11% below its summer high. For investors, the more useful question is not whether biotech is in a bull market, but which parts of it are, and what could break the trend.
What Actually Drove the Rally
Three forces did most of the work. The first was clinical and commercial success. Investors bid up shares on therapeutic breakthroughs and new-product launches, with the sharpest single jolt coming on Aug. 19, when Moderna’s stock nearly tripled on late-stage results for the mRNA cancer vaccine it is developing with Merck.
The second was consolidation. Large drugmakers facing a patent cliff that threatens $300 billion to $400 billion in sales beginning around 2028 have been buying pipelines rather than building them. Deal value reached $117.7 billion in the first half of 2026, well ahead of $64.2 billion in the same period a year earlier, and 2026 is tracking to become the second most active biopharma M&A year on record at an annualized pace of about $241 billion. That created what Stifel analysts call a “generalist fear of missing out,” as non-specialist funds piled into biotech to capture acquisition premiums.
The third was capital access. Global public issuance reached $80 billion across 974 deals year to date, and 23 biotechs completed IPOs in the first three quarters — nearly three times the full-year 2025 total of eight.
Why the Rally Stalled After August
The pullback is not a story of collapsing fundamentals. It is a story of macroeconomics and deal flow. On Sept. 16, the Federal Reserve raised its target range by 25 basis points to 3.75–4.00%, its first increase since 2023, while the 10-year Treasury yield closed at 5.27% on Oct. 6, its highest level since 2007. Higher discount rates hit pre-revenue companies hardest, because their value rests almost entirely on future cash flows.
At the same time, monthly M&A dollar volume fell from nearly $45 billion in April to under $2 billion in September, removing the valuation floor that takeover speculation had provided. RBC Capital Markets analyst Brian Abrahams attributed the pullback “in large part” to that decline, compounded by rising rates and a more risk-off market. Developmental biotechs were hit hardest: IBD’s 541-company Medical-Development Biotech group fell as much as 21% from its August peak, versus 13% for revenue-generating biotechs and 9% for profitable ones.
The divergence is stark at the company level, too. STAT’s Adam Feuerstein noted on Oct. 15 that the XBI was still up 24% for the year but down 11% from its August high, and that the real trouble lay beneath the index’s performance.
Sentiment Is Upbeat — Even Among Skeptics
Industry insiders, unusually, are more optimistic than the stock chart suggests. The Endpoints News Biopharma Sentiment Index rose to 105 in the third quarter from 96, crossing into positive territory for the first time since the post-pandemic downturn, with current-conditions scores jumping to 103 from 87. Dealmaking was the most-cited reason for optimism for the third consecutive survey, chosen by 38% of respondents, and 57% expect more deals a year from now.
That survey also contains a warning worth heeding. Asked where they would put $20,000 of their own money to maximize returns over the next year, only 15% of biopharma insiders chose biotech — the same share as before the rally began. An S&P 500 fund was the top pick at 42%, followed by a technology fund at 25%. Investors and finance professionals scored 126 and 127 on the sentiment index, while scientists scored 87 and big pharma employees 80, the widest gap since the survey began.
The New Geopolitical Variable: China
The sector’s biggest new risk arrived on Oct. 22, when the U.S. Treasury Department proposed rules adding biotechnology to the industries covered by the Comprehensive Outbound Investment National Security (COINS) Act. The proposal would prohibit U.S. companies from entering financial transactions with Chinese biotech firms and Chinese manufacturers of biotech equipment and tools, covering bio-derived compounds, biomanufacturing equipment, biological design and sequencing technology, and software for automated scientific discovery.
Crucially, the rule does not address licensing deals, a Treasury official told reporters, though the department declined to clarify how it would treat co-development and co-marketing agreements. That distinction matters enormously: about a third of new drugs under development globally originate in China, and companies including Pfizer, Bristol Myers Squibb and Roche have signed multibillion-dollar licensing deals with Chinese firms this year. PhRMA has argued against investment limits, with vice president Jocelyn Ulrich telling Politico that “the ecosystem includes a lot of promising science from China right now”.
Beijing has moved in parallel, proposing to restrict foreign access to domestic cell-and-gene therapy technologies through licensing rather than outright sale, a step analysts read as both industrial policy and a potential retaliatory lever. The proposal must by law be finalized by March, and its terms could still change.
What Comes Next — and What to Watch
The bull case for the rest of the year rests on three pillars, according to Stifel: an improving macro backdrop if oil and inflation ease, a resumption of M&A after the November midterm elections, and artificial intelligence as a long-cycle productivity driver. RBC’s Abrahams likewise expects a seasonal winter pickup in dealmaking, noting that first and fourth quarters have historically carried the heaviest M&A volumes. Moody’s estimates pharmaceutical companies held $175 billion in cash, short-term investments and free cash flow at the end of 2025, with AbbVie, Eli Lilly and Johnson & Johnson best positioned to fund $2 billion to $10 billion bolt-on deals without damaging their balance sheets.
For investors weighing exposure, the data points to a few practical distinctions. Large, diversified biotech and profitable companies have held up far better than early-stage developers, and the valuation gap between companies with strong clinical data and those with mediocre data has widened to 29-to-1 on average enterprise value. Sector ETFs such as XBI and IBB offer broad exposure but carry the same rate sensitivity as the underlying group. The IPO window has reopened, but selectively: of 23 biotechs that listed this year, 16 now trade above their offer price, with a median return of 12%.
The risks are equally concrete. A further Fed hike, a renewed oil shock tied to the Strait of Hormuz, a slower-than-expected return of dealmaking, or a broader U.S.-China escalation over biotech investment could each pressure valuations again. Political risk is also rising into year-end, with drug pricing historically a bipartisan target after midterm elections.
The most defensible reading of the evidence is that biotech’s 2026 gains are real and grounded in science and deal economics, but that the easy phase of the rally has passed. The sector is no longer uniformly surging; it is sorting, with capital flowing toward validated clinical programs and away from stories.
